(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.26%) $78.18
(0.23%) $2.21
(0.02%) $2 324.70
(0.17%) $27.59
(-0.03%) $988.10
(0.16%) $0.931
(0.35%) $10.94
(0.18%) $0.801
(-0.01%) $91.43
0.00% $ 38.39
Live Chart Being Loaded With Signals
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 200.00 |
Średni wolumen | 13.00 |
Kapitalizacja rynkowa | 0.00 |
Last Dividend | $0.411 ( 2022-05-12 ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Vifor Pharma AG Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Vifor Pharma AG Finanse
Annual | 2021 |
Przychody: | $1.82B |
Zysk brutto: | $1.15B (63.18 %) |
EPS: | $0.445 |
FY | 2021 |
Przychody: | $1.82B |
Zysk brutto: | $1.15B (63.18 %) |
EPS: | $0.445 |
FY | 2020 |
Przychody: | $1.71B |
Zysk brutto: | $1.00B (58.89 %) |
EPS: | $1.108 |
FY | 2019 |
Przychody: | $1.88B |
Zysk brutto: | $1.12B (59.44 %) |
EPS: | $0.490 |
Financial Reports:
No articles found.
Vifor Pharma AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.371 | 2016-05-02 |
Last Dividend | $0.411 | 2022-05-12 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 6 | -- |
Total Paid Out | $2.44 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.16 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 2.49 | |
Div. Directional Score | 6.33 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OSCUF | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
CYFL | Ex Dividend Knight | 2023-09-05 | Quarterly | 0 | 0.00% | |
UEPCN | Ex Dividend Knight | 2023-07-20 | Quarterly | 0 | 0.00% | |
JARLF | Ex Dividend Knight | 2023-08-17 | Semi-Annually | 0 | 0.00% | |
BDNNY | Ex Dividend Junior | 2023-05-09 | Semi-Annually | 0 | 0.00% | |
RDEIY | Ex Dividend Knight | 2023-06-29 | Semi-Annually | 0 | 0.00% | |
ENBFF | Ex Dividend Knight | 2023-08-14 | Quarterly | 0 | 0.00% | |
WLWHY | Ex Dividend Junior | 2023-09-21 | Annually | 0 | 0.00% | |
LDSCY | Ex Dividend Junior | 2023-08-24 | Quarterly | 0 | 0.00% | |
BZZUY | Ex Dividend Knight | 2023-05-25 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.145 | 1.500 | 7.09 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0520 | 1.200 | 8.27 | 9.92 | [0 - 0.3] |
returnOnEquityTTM | 0.0752 | 1.500 | -0.276 | -0.414 | [0.1 - 1] |
payoutRatioTTM | 0.715 | -1.000 | 2.85 | -2.85 | [0 - 1] |
currentRatioTTM | 1.914 | 0.800 | 5.43 | 4.34 | [1 - 3] |
quickRatioTTM | 1.013 | 0.800 | 8.75 | 7.00 | [0.8 - 2.5] |
cashRatioTTM | 1.013 | 1.500 | 5.49 | 8.23 | [0.2 - 2] |
debtRatioTTM | 0.115 | -1.500 | 8.08 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 22.19 | 1.000 | 2.89 | 2.89 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.622 | 2.00 | 9.46 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.949 | 2.00 | 9.53 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.168 | -1.500 | 9.33 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.632 | 1.000 | 2.80 | 2.80 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.109 | 1.000 | 9.81 | 9.81 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.898 | 1.000 | 6.12 | 6.12 | [0.2 - 2] |
assetTurnoverTTM | 0.358 | 0.800 | -0.948 | -0.758 | [0.5 - 2] |
Total Score | 10.18 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 42.63 | 1.000 | 5.80 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0752 | 2.50 | -0.177 | -0.414 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.949 | 2.00 | 9.68 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.622 | 2.00 | 9.46 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.715 | 1.500 | 2.85 | -2.85 | [0 - 1] |
pegRatioTTM | -2.43 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.289 | 1.000 | 5.27 | 0 | [0.1 - 0.5] |
Total Score | 2.49 |
Vifor Pharma AG
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of March 22, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej